Lilly's CYRAMZA (ramucirumab) significantly improved overall survival in phase 3 non-small cell lung cancer study. Results from the REVEL trial were published in The Lancet and also presented at ASCO ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. This story was originally published on BioPharma Dive. To ...

(RTTNews) - Eli Lilly and Co. (LLY) Monday announced the presentation of its final survival results of MONARCH 3 clinical trial that evaluated Verzenio at the 2023 San Antonio Breast Cancer Symposium.

Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, improved overall survival in a late-stage trial for certain patients with ...

Results from MONARCH 3 show a numerical improvement in overall survival (OS) of 13.1 months for women with HR+, HER2- metastatic breast cancer treated with Verzenio plus an aromatase inhibitor in the ...